PAR · ASX

Paradigm Biopharmaceuticals Ltd. (ASX:PAR)

AU$0.32

 -0.02 (-5.97%)
ASX:Live
18/08/2025 04:10:06 PM
Hammer Bullish Hammer Bearish HALO Ords HALO Growth HALO Earnings Momentum +4
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PAR Overview

PAR Health Scores

Short Term

Mean Reversion

Very Weak

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Strong

Quality

Capital Efficiency

Neutral

Balance Sheet

Very Strong

About PAR

Website

Paradigm Biopharmaceuticals Ltd.

Telephone

61.3.9629.5566

Address

Level 15 500 Collins Street Melbourne, Victoria (VIC) 3000

Description

Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. It is a drug repurposing company which seeks to find new uses for old drugs. The company was founded by Paul John Rennie on May 2, 2014 and is headquartered in Melbourne, Australia.

PAR Price Chart

Key Stats

Market Cap

AU$125.19M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.17 - 0.66

Trade Value (12mth)

AU$130,798.00

1 week

13.56%

1 month

-20.24%

YTD

-16.25%

1 year

45.65%

All time high

4.35

Key Fundamentals

EPS 3 yr Growth

23.80%

EBITDA Margin

%

Operating Cashflow

-$66m

Free Cash Flow Return

-169.40%

ROIC

-150.70%

Interest Coverage

-4,477.80

Quick Ratio

7.20

Other Data

Shares on Issue (Fully Dilluted)

354m

HALO Sector

Healthcare

Next Company Report Date

29-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

1.40

PAR Announcements

Latest Announcements

Date Announcements

31 July 25

Investor Webinar Presentation

×

Investor Webinar Presentation

29 July 25

June 2025 Quarterly Activities Report & Appendix 4C

×

June 2025 Quarterly Activities Report & Appendix 4C

24 July 25

Paradigm Investor Webinar

×

Paradigm Investor Webinar

22 July 25

Application for quotation of securities - PAR

×

Application for quotation of securities - PAR

07 July 25

Notification regarding unquoted securities - PAR

×

Notification regarding unquoted securities - PAR

07 July 25

Notice under Section 708A

×

Notice under Section 708A

02 July 25

Application for quotation of securities - PAR

×

Application for quotation of securities - PAR

02 July 25

Notice under Section 708A

×

Notice under Section 708A

01 July 25

Paradigm Secures US$27M to Advance Phase 3 OA Trial

×

Paradigm Secures US$27M to Advance Phase 3 OA Trial

01 July 25

Proposed issue of securities - PAR

×

Proposed issue of securities - PAR

01 July 25

Proposed issue of securities - PAR

×

Proposed issue of securities - PAR

30 June 25

US Sites Activated and Patients Consented

×

US Sites Activated and Patients Consented

26 June 25

Paradigm Strengthens OA Pipeline with Strategic Acquisition

×

Paradigm Strengthens OA Pipeline with Strategic Acquisition

03 June 25

Phase 3 Knee OA Trial Begins, Site Live, Patient Consented

×

Phase 3 Knee OA Trial Begins, Site Live, Patient Consented

29 May 25

Results of Meeting

×

Results of Meeting

15 May 25

PAR Receives US Ethics Approval for Phase 3

×

PAR Receives US Ethics Approval for Phase 3

29 April 25

March 2025 Quarterly Activities Report & Appendix 4C

×

March 2025 Quarterly Activities Report & Appendix 4C

29 April 25

Notice of General Meeting/Proxy Form

×

Notice of General Meeting/Proxy Form

18 March 25

Paradigm to present at NWR Healthcare Conference

×

Paradigm to present at NWR Healthcare Conference

14 March 25

Application for quotation of securities - PAR

×

Application for quotation of securities - PAR

07 March 25

S&P DJI Announces March 2025 Quarterly Rebalance

×

S&P DJI Announces March 2025 Quarterly Rebalance

28 February 25

Appendix 4D and Half Year Report

×

Appendix 4D and Half Year Report

24 February 25

Paradigm Secures Ethics Approval for Phase 3 Trial

×

Paradigm Secures Ethics Approval for Phase 3 Trial

14 February 25

Change of Director's Interest Notice

×

Change of Director's Interest Notice

14 February 25

Change of Director's Interest Notice

×

Change of Director's Interest Notice

PAR Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.16 -0.18 -0.20 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.16 -0.18 -0.20 Lock Lock Lock
     Growth % Lock Lock Lock Lock -0.8 -10.0 -11.6 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.15 -0.17 -0.16 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.13 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -16.1 -14.7 6.3 Lock Lock Lock
     Yield % Lock Lock Lock Lock -14.3 0.0 0.0 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.18 0.19 0.07 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.16 0.18 0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock -48.4 7.2 -66.0 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 242 290 293 Lock Lock Lock
Basic m Lock Lock Lock Lock 241 290 293 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 285.5 -41.0 40.7 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 47 59 64 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 10.7 51.2 28.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -325.4 -268.9 -136.7 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 425 369 237 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -47 -59 -64 Lock Lock Lock
     Growth % Lock Lock Lock Lock -11.1 -26.2 -8.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -59,095.0 -126,309.1 -97,790.3 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -47 -59 -64 Lock Lock Lock
     Growth % Lock Lock Lock Lock -11.0 -26.0 -8.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -59,339.0 -126,637.7 -98,013.3 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -47 -59 -65 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -8 -7 -6 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -39 -52 -59 Lock Lock Lock
     Growth % Lock Lock Lock Lock -14.4 -32.3 -13.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -49,542.5 -111,013.7 -89,138.6 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -32 -45 -66 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 63 28 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -32 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 7.9 100.0 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock -406.5 0.0 0.0 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 40 56 18 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 51 67 27 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -39 -56 -18 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 8 13 4 Lock Lock Lock
Equity $m Lock Lock Lock Lock 42 54 24 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 43 54 24 Lock Lock Lock
     Growth % Lock Lock Lock Lock -45.8 26.0 -55.6 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -77.4 -77.4 -214.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -92.8 -96.7 -246.4 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -77.1 -122.2 -165.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -64.5 -107.4 -150.7 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -52.9 -93.5 -169.4 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -1,635.1 -3,597.8 -4,477.8 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.8 0.9 0.3 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -92.4 -104.4 -74.0 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 6.0 4.9 7.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 6.0 4.9 7.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 84.2 88.4 73.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -411.3 -346.5 -1,962.7 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 8,947.1 26,007.7 4,287.5 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -59,340.8 -126,074.0 -98,328.7 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -92.7 -87.9 -236.2 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -77.4 -77.4 -214.1 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.2 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -92.8 -96.7 -246.4 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -92.8 -96.7 -246.4 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 35,075.5 52,791.1 32,977.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 35,075.5 52,791.1 32,977.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 6,541.2 20,391.1 17,548.1 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 28,534.3 32,400.1 15,429.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.19%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

-0.10%

3 Month Change

-0.10%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PAR Shortsell

Frequently Asked Questions

The current share price of Paradigm Biopharmaceuticals Ltd. (PAR:ASX) is AU$0.32.
The 52-week high share price for Paradigm Biopharmaceuticals Ltd. (PAR:ASX) is AU$0.66.
The 52-week low share price for Paradigm Biopharmaceuticals Ltd. (PAR:ASX)? is AU$0.17.
Paradigm Biopharmaceuticals Ltd. (PAR:ASX) does not pay a dividend.
Paradigm Biopharmaceuticals Ltd. (PAR:ASX) does not pay a dividend.
Paradigm Biopharmaceuticals Ltd. (PAR:ASX) has a franking level of 0.0%.
Paradigm Biopharmaceuticals Ltd. (PAR:ASX) is classified in the Healthcare.
The current P/E ratio for Paradigm Biopharmaceuticals Ltd. (PAR:ASX) is .
The current share price of Paradigm Biopharmaceuticals Ltd. (PAR:ASX) is AU$0.32.
The 52-week high share price for Paradigm Biopharmaceuticals Ltd. (PAR:ASX) is AU$0.66.
The 52-week low share price for Paradigm Biopharmaceuticals Ltd. (PAR:ASX)? is AU$0.17.
Paradigm Biopharmaceuticals Ltd. (PAR:ASX) does not pay a dividend.
Paradigm Biopharmaceuticals Ltd. (PAR:ASX) does not pay a dividend.
Paradigm Biopharmaceuticals Ltd. (PAR:ASX) has a franking level of 0.0%.
Paradigm Biopharmaceuticals Ltd. (PAR:ASX) is classified in the Healthcare.
The current P/E ratio for Paradigm Biopharmaceuticals Ltd. (PAR:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.